300255 常山药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-2.623-50.9360.5727.8969.090
总资产报酬率 ROA (%)-1.001-23.3290.3124.7855.939
投入资产回报率 ROIC (%)-1.103-25.3300.3345.1546.039

边际利润分析
销售毛利率 (%)15.85022.50244.42158.18168.667
营业利润率 (%)-7.786-86.9460.8758.82713.081
息税前利润/营业总收入 (%)0.105-80.7374.81011.21815.566
净利润/营业总收入 (%)-8.261-88.4940.4357.79210.625

收益指标分析
经营活动净收益/利润总额(%)158.43248.289164.29596.535101.161
价值变动净收益/利润总额(%)0.000-0.0010.0000.0000.000
营业外收支净额/利润总额(%)2.9560.436-12.896-0.610-2.533

偿债能力分析
流动比率 (X)1.0161.1852.1801.9662.124
速动比率 (X)0.3910.3290.8200.6480.788
资产负债率 (%)63.29260.84649.40240.80537.601
带息债务/全部投入资本 (%)56.18554.90444.55835.746--
股东权益/带息债务 (%)72.30079.332121.839176.804213.320
股东权益/负债合计 (%)58.39364.777102.558144.909165.622
利息保障倍数 (X)0.013-12.2521.1924.5905.542

营运能力分析
应收账款周转天数 (天)80.14177.32453.40241.2780.000
存货周转天数 (天)584.577671.176653.827605.0080.000